Built by Scientists & Operators.
Proven leaders in epigenetics, single-molecule imaging, and biotech commercialization — with decades of combined experience translating frontier science into real-world diagnostics.
Meet the Founders
Serial entrepreneur with two decades experience in single-molecule biotechnology companies — from concept through public stage. Expertise in platform development, commercialization, and capital formation.
- Founder & former CEO, SeqLL Inc. (NASDAQ: SQL)
- Previously at Helicos Biosciences, US Genomics, Exact Sciences
- Track record: concept → NASDAQ listing for single-molecule platform
World-class epigenetics researcher and inventor of the core platform technology. Published the foundational clinical validation data in Nature Biotechnology. Leading scientific development and assay innovation.
- Principal Investigator, Weizmann Institute of Science, Israel
- Principal Investigator, Max Planck Institute for Molecular Genetics, Germany
- Inventor of EPINUC — Nature Biotechnology, 2022
Biotech instrumentation and medical device expert. Specialist in single-molecule system design, manufacturing, and regulatory-grade quality systems. Leading platform engineering and instrument development.
- Previously at Ivenix, Helicos Biosciences, CambridgeEndo
- Expert in single-molecule instrumentation & design
- Medical device QMS and manufacturing scale-up
What Our Founders Brings
Three critical disciplines — science, engineering, and company-building.
The Science
Deep domain expertise in histone modifications, nucleosome biology, and the epigenetic basis of cancer — from the scientist who invented the platform.
The Instrument
TIRF microscopy, fluorescence detection, surface chemistry, and microfluidics — the core instrumentation capabilities that make single-molecule readout possible at clinical grade.
Manufacturing at Scale
Design-for-manufacturing expertise to transition from research-grade prototypes to clinical-grade, GMP-compliant instruments at production scale.
Regulatory & Clinical
Direct experience with FDA BDD submissions, CLIA/CAP certification, clinical study design, and the regulatory pathways specific to liquid biopsy IVDs.
Company Building
A founder-CEO who has taken a single-molecule technology from concept through NASDAQ listing — including fundraising, team building, and board governance.
Pharma & Clinical Network
Combined relationships spanning oncology pharma, diagnostic distributors, and academic medical centers — the key stakeholders for our dual-market strategy.
By the Numbers
Decades of hard-won experience across the disciplines that matter most.
We're Building an Advisory Board
Actively recruiting strategic advisors across oncology, regulatory affairs, reimbursement, and BioPharma business development. If you bring relevant expertise and want to shape the future of cancer diagnostics, we'd welcome a conversation.